Global Bromine-77 Market Strategic Research Report

Scope of the Report

The global Bromine-77 market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

In 2025, global production of bromine-77 was approximately 37 grams, with an average global market price of about US$44,000 per gram. Total global production capacity of bromine-77 reached approximately 65 grams in 2025. The industry average gross profit margin for this product was approximately 62%. Bromine-77 (^77Br) is an artificially produced radioactive isotope of bromine with an atomic number of 35 and a mass number of 77. Unlike naturally occurring stable bromine isotopes (^79Br and ^81Br), Bromine-77 is mainly produced through nuclear reactions, such as irradiation of enriched Selenium-77 (^77Se) targets with proton beams or other accelerated particles. With a moderate half-life of approximately 57 hours, Bromine-77 undergoes electron capture decay and emits characteristic gamma radiation, making it valuable for nuclear medicine research, radiopharmaceutical development, isotope tracing, and fundamental radiochemistry studies. Due to its relatively short half-life and limited production and transportation window, Bromine-77 is considered a specialized, low-volume, high-technology radioactive isotope product.

The upstream segment of the Bromine-77 industry mainly includes isotope production materials, nuclear reaction targets, accelerator facilities, and nuclear infrastructure suppliers. Key raw materials include high-purity Selenium-77 targets, enriched selenium isotopes, and related chemical reagents. The availability of enriched Selenium-77 directly influences Bromine-77 production capacity. Production typically relies on cyclotrons, research reactors, or other nuclear reaction facilities, followed by radiochemical separation, purification, and quality testing processes to obtain research-grade Bromine-77. Due to strict regulations regarding radioactive isotope production licenses, nuclear facility operation, and specialized technical expertise, the upstream supply chain has significant entry barriers, with only a limited number of global facilities capable of stable production. The midstream segment mainly covers radioactive isotope production, radiochemical separation, purification, quality control, and specialized packaging and transportation services. Producers and research institutions typically supply Bromine-77 in different activity levels and chemical forms, such as bromide solutions, radiolabeling precursors, or customized research samples. Because of its short half-life, midstream suppliers must have rapid production capabilities, efficient quality testing procedures, and specialized radioactive logistics systems to ensure timely delivery. The main value creation areas include nuclear reaction optimization, radiochemical processing technology, radioactive purity control, and compliance with international radioactive material transportation standards. The downstream applications of Bromine-77 mainly focus on nuclear medicine research, radiopharmaceutical development, molecular imaging, and life science studies. In nuclear medicine, Bromine-77 can serve as a radioactive tracer for studying drug distribution, metabolic pathways, and biological molecular behavior, while also supporting the development of new radiopharmaceutical candidates. In addition, Bromine-77 is used in radiochemistry, nuclear physics experiments, and isotope labeling research. With the continued development of targeted radiotherapy, precision medicine, and advanced nuclear medicine technologies, demand for specialized radionuclides is expected to increase. As a research-oriented radionuclide with unique nuclear characteristics, Bromine-77 is expected to maintain steady growth driven primarily by scientific research and pharmaceutical innovation.

The primary growth drivers of the Bromine-77 industry come from the continuous expansion of nuclear medicine and radiopharmaceutical research. With the rapid development of precision medicine, molecular imaging, and targeted therapies, global demand for specialized radionuclides continues to increase. Due to its unique decay characteristics and chemical labeling capabilities, Bromine-77 can be used as a radioactive tracer to study drug distribution, metabolic pathways, and biological mechanisms, while also supporting the development of novel radiopharmaceutical candidates. The shift toward personalized and precision-based cancer diagnosis and treatment has encouraged research institutions and pharmaceutical companies to increase investment in specialized radionuclide resources.

Advances in radioactive isotope production technologies represent a key factor supporting the development of Bromine-77. Production of Bromine-77 relies mainly on enriched Selenium-77 target materials and nuclear reaction facilities such as cyclotrons. Its supply capability is influenced by target preparation, irradiation efficiency, radiochemical separation, and quality control technologies. With increasing investment in medical isotope production infrastructure, wider deployment of advanced cyclotrons, and improvements in automated radiochemistry systems, the production efficiency and quality consistency of Bromine-77 continue to improve. Meanwhile, stronger collaboration among nuclear medicine centers worldwide is enhancing the supply capability of short-lived radionuclides.

In the future, the Bromine-77 industry is expected to develop as a small-volume, high-value, application-driven isotope market. Due to its relatively short half-life, Bromine-77 is unlikely to develop into a large-scale inventory-based commodity and will continue to rely on project-based demand, preclinical research, and customized supply models. Future growth opportunities will mainly come from innovative radiopharmaceutical development, targeted radionuclide therapy (TRT), molecular probe research, and fundamental nuclear medicine studies. As new therapeutic targets continue to emerge, demand for specialized radioactive labeling materials with unique nuclear properties is expected to increase.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Bromine-77 market?

What factors are driving Bromine-77 market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Bromine-77 market opportunities vary by end market size?

How does Bromine-77 break out by Type, by Application?

This report presents a comprehensive overview of the global Bromine-77 market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Solution
• Solid Target

Segment by Radioactivity

• Low Activity Bromine-77
• Medium Activity Bromine-77
• High Activity Bromine-77

Segment by Chemical Form

• Bromine-77 Bromide
• Organobromine-77 Compounds
• Bromine-77 Radiopharmaceutical Precursors

Segment by Production Technology Route

• Selenium-77 Proton Bombardment Production
• Alternative Nuclear Reaction Production
• Reactor-Based Production

Segment by Application

• Imaging Agent
• Disease Treatment

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Bromine-77 market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Imaging Agent, Disease Treatment evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact